Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
复制标题
DOI：
10.1097/00002371-199601000-00009
复制
发表时间：
1996-01-01
影响因子：
3.9
通讯作者：
White, DE
中科院分区：
文献类型：
--
作者：
Rosenberg, SA;White, DE
对接受大剂量白介素2免疫治疗的转移性肾细胞癌和转移性黑色素瘤患者进行了白癜风的前瞻性评估。所有在NCI免疫治疗诊所外科分部就诊、随访至少1年的患者均被评估。74例转移性黑色素瘤患者中有11例(15%)出现白癜风(p(2)=0.0001)。在免疫治疗无效的27名患者中没有发现白癜风，尽管对基于IL-2的免疫治疗有客观反应的43名黑色素瘤患者中有11名(26%)出现了白癜风(p(2)=0.0002)。这些发现进一步证明，不断增长的黑色素瘤的存在可以使患者对黑素细胞分化抗原敏感，并且对这些抗原的免疫反应与接受免疫治疗的患者的癌症消退有关。
Patients with metastatic renal cell cancer and metastatic melanoma treated with high-dose interleukin-2-based immunotherapy were prospectively evaluated for the development of vitiligo. All patients seen in the Surgery Branch, NCI Immunotherapy Clinic, who had been followed for at least 1 year were evaluated. Of 104 patients with metastatic renal cancer none developed vitiligo, though vitiligo was seen in 11 of 74 (15%) patients with metastatic melanoma (p(2) = 0.0001). No vitiligo was seen in 27 patients who did not respond to immunotherapy, although vitiligo was seen in 11 of 43 (26%) melanoma patients who had an objective response to IL-2-based immunotherapy (p(2) = 0.0002). These findings provide further evidence that the presence of a growing melanoma can sensitize patients to melanocyte-differentiation antigens and that the immune response against these antigens is associated with cancer regression in patients undergoing immunotherapy.